Plasma tau in Alzheimer disease

Neurology

Volumn 87, Issue 17, 2016, Pages 1827-1835

  Mattsson, Niklas ^a,b   Zetterberg, Henrik ^c,d   Janelidze, Shorena ^a   Insel, Philip S ^a   Andreasson, Ulf ^c   Stomrud, Erik ^a,b   Palmqvist, Sebastian ^a,b   Baker, David ^e   Tan Hehir, Cristina A ^f   Jeromin, Andreas ^g   Hanlon, David ^g   Song, Linan ^g   Shaw, Leslie M ^h   Trojanowski, John Q ^h   Weiner, Michael W ^i,j   Hansson, Oskar ^a,b   Blennow, Kaj ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f GE GLOBAL RESEARCH   (United States)

^g QUANTERIX CORPORATION   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; BRAIN; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION DISORDERS; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 84992386036     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003246     Document Type: Article

References (23)

1. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36:297-309.
2. Mattsson N, Carrillo MC, Dean RA, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement Diagn Assess Dis Monit 2015;1:412-419.
3. Chiu MJ, Chen YF, Chen TF, et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 2014;35: 3132-3142.
4. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Tau is reduced in AD plasma and validation of employed ELISA methods. Am J Neurodegener Dis 2012;1:99-106.
5. Krishnan S, Rani P. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease. Biol Trace Elem Res 2014;158:158-165.
6. Tzen KY, Yang SY, Chen TF, et al. Plasma Ab but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci 2014;5:830-836.
7. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013;5:9.
8. Chiu MJ, Yang SY, Horng HE, et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. ACS Chem Neurosci 2013;4:1530-1536.
9. Wang T, Xiao S, Liu Y, et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. Int J Geriatr Psychiatry 2014;29:713-719.
10. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology; 2010;74:201-209.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain J Neurol 2015;138: 3373-3385.
13. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403-413.
14. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging JMRI 2008;27:685-691.
15. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578-586.
16. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid b-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282-1289.
17. Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015; 85:1240-1249.
18. Haftenberger M, Schuit AJ, Tormo MJ, et al. Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and nutrition (EPIC). Public Health Nutr 2002;5:1163-1176.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. Washington, DC: American Psychiatric Association; 1987.
20. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
21. Randall J, Mörtberg E, Provuncher GK, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation 2013;84:351-356.
22. Little R, Rubin D. Statistical Analysis With Missing Data. 2nd ed. Hoboken: Wiley; 2002.
23. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis 2011;26:627-645.